- Home
- TVTX vs BCAX Comparison
TVTX vs BCAX Comparison
Compare TVTX & BCAX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TVTX
- BCAX
- Stock Information
- Founded
- TVTX 2008
- BCAX 2018
- Country
- TVTX United States
- BCAX United States
- Employees
- TVTX N/A
- BCAX N/A
- Industry
- TVTX Biotechnology: Pharmaceutical Preparations
- BCAX
- Sector
- TVTX Health Care
- BCAX
- Exchange
- TVTX Nasdaq
- BCAX NYSE
- Market Cap
- TVTX 1.3B
- BCAX 1.3B
- IPO Year
- TVTX N/A
- BCAX 2024
- Fundamental
- Price
- TVTX $17.72
- BCAX $20.17
- Analyst Decision
- TVTX Buy
- BCAX Strong Buy
- Analyst Count
- TVTX 13
- BCAX 4
- Target Price
- TVTX $23.46
- BCAX $41.00
- AVG Volume (30 Days)
- TVTX 1.4M
- BCAX 274.3K
- Earning Date
- TVTX 10-31-2024
- BCAX 11-12-2024
- Dividend Yield
- TVTX N/A
- BCAX N/A
- EPS Growth
- TVTX N/A
- BCAX N/A
- EPS
- TVTX N/A
- BCAX N/A
- Revenue
- TVTX $203,447,000.00
- BCAX N/A
- Revenue This Year
- TVTX $62.45
- BCAX N/A
- Revenue Next Year
- TVTX $59.30
- BCAX N/A
- P/E Ratio
- TVTX N/A
- BCAX N/A
- Revenue Growth
- TVTX 57.08
- BCAX N/A
- 52 Week Low
- TVTX $5.12
- BCAX $18.33
- 52 Week High
- TVTX $20.33
- BCAX $28.09
- Technical
- Relative Strength Index (RSI)
- TVTX 51.53
- BCAX N/A
- Support Level
- TVTX $16.89
- BCAX N/A
- Resistance Level
- TVTX $19.51
- BCAX N/A
- Average True Range (ATR)
- TVTX 1.23
- BCAX 0.00
- MACD
- TVTX -0.16
- BCAX 0.00
- Stochastic Oscillator
- TVTX 26.69
- BCAX 0.00
About TVTX Travere Therapeutics Inc.
Travere Therapeutics Inc is a biopharmaceutical company. The company is focused on identifying, developing and delivering life-changing therapies to people living with rare kidney, liver, and metabolic diseases. Its pipeline candidate, sparsentan, is an investigational product candidate in late-stage development for focal segmental glomerulosclerosis (FSGS) and IgA nephropathy (IgAN) - rare kidney disorders that often cause end-stage kidney disease.
About BCAX BICARA THERAPEUTICS INC
Bicara Therapeutics Inc is a clinical-stage biopharmaceutical company bringing transformative bifunctional therapies to patients with solid tumors. Its program ficerafusp alfa is a bifunctional antibody that combines two clinically validated targets, an epidermal growth factor receptor, or EGFR, directed monoclonal antibody with a domain that binds to human transforming growth factor beta, or TGF-b.